The association of Raynaud's syndrome with cisplatin-based chemotherapy - A meta-analysis

European Journal of Internal Medicine

Volumn 23, Issue 7, 2012, Pages 594-598

  Mohokum, Melvin ^a   Hartmann, Peter ^a   Schlattmann, Peter ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Cisplatin based chemotherapy; Meta analysis; Prevalence; Raynaud's phenomenon; Raynaud's syndrome

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; VINBLASTINE; VINCRISTINE;

CANCER CHEMOTHERAPY; CASE CONTROL STUDY; DRUG SAFETY; HUMAN; HYPOMAGNESEMIA; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

EID: 84865684389     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2012.03.016     Document Type: Short Survey

References (32)

1. J.A. Block, and W. Sequeira Raynaud's phenomenon Lancet 357 2001 2042 2048
2. H. Heidrich Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia Vasa 39 2010 33 41
3. L. Fraenkel Raynaud's phenomenon: epidemiology and risk factors Curr Rheumatol Rep 4 2002 123 128
4. D.C. Doll, and J.W. Yarbro Vascular toxicity associated with antineoplastic agents Semin Oncol 19 1992 580 596
5. S.W. Hansen, and N. Olsen Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold J Clin Oncol 7 1989 940 942
6. N.J. Vogelzang, J.L. Torkelson, and B.J. Kennedy Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin Cancer 56 1985 2765 2770
7. M. Rozencweig, D.D. von Hoff, M. Slavik, and F.M. Muggia Cis-diamminedichloroplatinum (II). A new anticancer drug Ann Intern Med 86 1977 803 812
8. M.S. Heier, T. Nilsen, V. Graver, N. Aass, and S.D. Fossa Raynaud's phenomenon after combination chemotherapy of testicular cancer, measured by laser Doppler flowmetry. A pilot study Br J Cancer 63 1991 550 552
9. G.J. Bosl, N.L. Geller, and D. Bajorin A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors J Clin Oncol 6 1988 1231 1238
10. R. de Wit, G. Stoter, and S.B. Kaye Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group J Clin Oncol 15 1997 1837 1843
11. R. Eeles, D.M. Tait, and M.J. Peckham Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer Cancer Treat Rep 70 1986 905 907
12. Schwarzer G. meta: Meta-Analysis with R. In. 1.5-0 ed; 2010: Fixed and random effects meta-analysis. Functions for tests of bias, forest and funnel plot.
13. J.P. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
14. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560
15. R. DerSimonian, and N. Laird Meta-analysis in clinical trials Control Clin Trials 7 1986 177 188
16. P. Schlattmann Medical applications of finite mixture models 2009 Springer-Verlag Berlin Heidelberg
17. R.F. Galbraith Graphical display of estimates having differing standard errors Technometrics 30 1988 271 281
18. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test BMJ 315 1997 629 634
19. S.G. Thompson How should meta-regression analyses be undertaken and interpreted Stat Med 21 2002 1559 1573
20. Lumley T. rmeta: Meta-analysis. In. 2.16 ed; 2009.
21. Schlattmann P. Finite Mixture Models and metaanalysis tools - based on C.A.MAN. In. 0.64 ed; 2008.
22. A. Liberati, D.G. Altman, and J. Tetzlaff The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 339 2009 b2700
23. M.C. Weinrich, H.R. Maricq, J.E. Keil, A.R. McGregor, and F. Diat Prevalence of Raynaud phenomenon in the adult population of South Carolina J Clin Epidemiol 43 1990 1343 1349
24. R. De Angelis, F. Salaffi, and W. Grassi Raynaud's phenomenon: prevalence in an Italian population sample Clin Rheumatol 25 2006 506 510
25. L.G. Suter, J.M. Murabito, D.T. Felson, and L. Fraenkel The incidence and natural history of Raynaud's phenomenon in the community Arthritis Rheum 52 2005 1259 1263
26. S.W. Hansen, N. Olsen, N. Rossing, and M. Rorth Vascular toxicity and the mechanism underlying Raynaud's phenomenon in patients treated with cisplatin, vinblastine and bleomycin Ann Oncol 1 1990 289 292
27. N.J. Vogelzang, G.J. Bosl, K. Johnson, and B.J. Kennedy Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer Ann Intern Med 95 1981 288 292
28. T. Stefenelli, R. Kuzmits, W. Ulrich, and D. Glogar Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer Eur Heart J 9 1988 552 556
29. K. Pliarchopoulou, and D. Pectasides Late complications of chemotherapy in testicular cancer Cancer Treat Rev 36 2010 262 267
30. M.S. Chung, H.S. Gong, and G.H. Baek Prevalence of Raynaud's phenomenon in patients with idiopathic carpal tunnel syndrome J Bone Joint Surg Br 81 1999 1017 1019
31. H.R. Maricq, P.H. Carpentier, and M.C. Weinrich Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison J Rheumatol 24 1997 879 889
32. H.R. Maricq, P.H. Carpentier, and M.C. Weinrich Geographic variation in the prevalence of Raynaud's phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France J Rheumatol 20 1993 70 76